financetom
Technology
financetom
/
Technology
/
The Analyst Verdict: Onto Innovation In The Eyes Of 4 Experts
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
The Analyst Verdict: Onto Innovation In The Eyes Of 4 Experts
Oct 2, 2024 10:33 PM

In the latest quarter, 4 analysts provided ratings for Onto Innovation ( ONTO ) , showcasing a mix of bullish and bearish perspectives.

The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.

Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish
Total Ratings 2 2 0 0 0
Last 30D 0 1 0 0 0
1M Ago 0 1 0 0 0
2M Ago 1 0 0 0 0
3M Ago 1 0 0 0 0

Analysts have recently evaluated Onto Innovation ( ONTO ) and provided 12-month price targets. The average target is $258.75, accompanied by a high estimate of $275.00 and a low estimate of $230.00. This current average has increased by 6.34% from the previous average price target of $243.33.

Interpreting Analyst Ratings: A Closer Look

The standing of Onto Innovation ( ONTO ) among financial experts becomes clear with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.

Analyst Analyst Firm Action Taken Rating Current Price Target Prior Price Target
Edward Yang Oppenheimer Raises Outperform $275.00 $260.00
Edward Yang Oppenheimer Announces Outperform $260.00 -
Mark Miller Benchmark Maintains Buy $230.00 $230.00
Brian Chin Stifel Raises Buy $270.00 $240.00

Key Insights:

Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Onto Innovation ( ONTO ). This offers insight into analysts' perspectives on the current state of the company.

Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Onto Innovation ( ONTO ) compared to the broader market.

Price Targets: Analysts navigate through adjustments in price targets, providing estimates for Onto Innovation's ( ONTO ) future value. Comparing current and prior targets offers insights into analysts' evolving expectations.

To gain a panoramic view of Onto Innovation's ( ONTO ) market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.

Stay up to date on Onto Innovation ( ONTO ) analyst ratings.

Unveiling the Story Behind Onto Innovation

Onto Innovation Inc ( ONTO ) is engaged in the design, development, manufacture, and support of high-performance control metrology, defect inspection, lithography, and data analysis systems used by microelectronics device manufacturers. The Company and its subsidiaries currently operate in a single operating segment. The company mainly operates in the United States, Southeast Asia, China, Japan, and Europe, with Taiwan and South Korea the largest sources of total revenue.

Financial Insights: Onto Innovation

Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.

Revenue Growth: Onto Innovation's ( ONTO ) revenue growth over a period of 3 months has been noteworthy. As of 30 June, 2024, the company achieved a revenue growth rate of approximately 27.1%. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.

Net Margin: Onto Innovation's ( ONTO ) financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 21.85%, the company showcases strong profitability and effective cost management.

Return on Equity (ROE): Onto Innovation's ( ONTO ) ROE lags behind industry averages, suggesting challenges in maximizing returns on equity capital. With an ROE of 2.93%, the company may face hurdles in achieving optimal financial performance.

Return on Assets (ROA): Onto Innovation's ( ONTO ) ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.67% ROA, the company effectively utilizes its assets for optimal returns.

Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 0.01.

The Basics of Analyst Ratings

Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.

Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.

Breaking: Wall Street's Next Big Mover

Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Behind the Scenes of Marvell Tech's Latest Options Trends
Behind the Scenes of Marvell Tech's Latest Options Trends
May 28, 2024
Financial giants have made a conspicuous bullish move on Marvell Tech. ( MRVL ) Our analysis of options history for Marvell Tech ( MRVL ) revealed 35 unusual trades. Delving into the details, we found 77% of traders were bullish, while 14% showed bearish tendencies. Out of all the trades we spotted, 14 were puts, with a value of $1,236,880,...
Israel's Elbit reports strong quarter but shares weaken amid Gaza war backlash
Israel's Elbit reports strong quarter but shares weaken amid Gaza war backlash
May 28, 2024
JERUSALEM, May 28 (Reuters) - Israeli defence electronics firm Elbit Systems reported higher first-quarter sales and earnings on Tuesday on strong wartime demand and said it would hit a $7 billion sales target ahead of schedule. Elbit, one of Israel's largest defence contractors, supplies products ranging from drones to training simulators, artillery fire control systems and surveillance equipment and has...
Evaluating Dave: Insights From 6 Financial Analysts
Evaluating Dave: Insights From 6 Financial Analysts
May 28, 2024
In the last three months, 6 analysts have published ratings on Dave ( DAVE ) , offering a diverse range of perspectives from bullish to bearish. The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 0 6...
Musk's Neuralink registers brain implant study on US government database
Musk's Neuralink registers brain implant study on US government database
May 28, 2024
(Reuters) - Elon Musk's brain-chip startup Neuralink has registered details about a study evaluating its device in patients on the U.S. government's database of clinical trials. Neuralink is testing its implant to give paralyzed patients the ability to use digital devices by thinking alone, a prospect that could help people with spinal cord injuries. The study was registered as a...
Copyright 2023-2026 - www.financetom.com All Rights Reserved